About Twelve Bio
Twelve Bio is a Healthcare company based in Copenhagen (Denmark) founded in 2019 by Stefano Stella and Guillermo Montoya, and was acquired by Ensoma in January 2023. CRISPR-Cas12a technology is applied to develop diagnostics and therapeutics. Twelve Bio has raised $2.57 million across 2 funding rounds from investors including Ensoma. The company has 10 employees. Twelve Bio was last valued at $6.93 million in September 2020. Its chief executive, as recorded, is Stefano Stella. Twelve Bio offers products and services including Engenious Platform. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Reagents and Kits and Proteomics. Its legal entity is ENSOMA APS.
Company details
Twelve Bio was established in 2019 as a spin-off from the Montoya group in Copenhagen, Denmark. Focus is placed on CRISPR-Cas12a, a protein that functions as a biological tool for detecting and modifying DNA sequences to generate new variants. Diagnostics and therapeutics are created using this technology. Support has been provided by organizations including the BioInnovation Institute, Novo Nordisk Fonden, and Novo Holdings. Operations center on biotechnology applications in healthcare.
- Headquarters Copenhagen, Denmark
- Employees 10
- Founders Stefano Stella, Guillermo Montoya
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website twelve.bio
- Social LinkedIn
- Acquired by Ensoma (Jan 2023)
- Legal Name Ensoma Aps
Products & Services of Twelve Bio
Twelve Bio offers a comprehensive portfolio of products and services, including Engenious Platform.
Platform that combines delivery and DNA editing for disease treatments.
Funding Insights of Twelve Bio
Twelve Bio has successfully raised a total of $2.57M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $2.57 million completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2.57M
- Total Rounds 2
- Last Round Seed — $2.57M
All 2 funding rounds of Twelve Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2020 | $2.57M | Seed | $6.93M | – | – |
| May 2020 | Seed | $58.47M | – | – |
| Date | Valuation | Stage |
|---|---|---|
| Sep 2020 | $6.93M | •••••••• |
| May 2020 | $58.47M | •••••••• |
Last known valuation $6.93M (Sep 2020). 1 investors in total: 1 institutional.
Investors in Twelve Bio
Twelve Bio has secured backing from 1 investor. Prominent investors backing the company include Ensoma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Provider of in vivo stem cell modification technologies and vector-based drug delivery tool | 2019 | ensoma.com | Boston, United States |
Investor details for Twelve Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Twelve Bio
2 people are tracked at Twelve Bio (2 in leadership); the tracked headcount is 10.
| Name | Role | Group |
|---|---|---|
Stefano Stella | Co-Founder & CEO | Leadership |
Guillermo Montoya | Co-Founder | Leadership |
Complete people profiles for Twelve Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Twelve Bio
5 dated milestones of Twelve Bio across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Twelve Bio is founded.
- Funding First funding round.
- Milestone Reaches Minicorn status.
- Funding Latest funding round, Seed, of $2.6M.
- Exit Acquired by Ensoma.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Twelve Bio
Twelve Bio was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Twelve Bio is headquartered in Copenhagen, Denmark.
Stefano Stella is the CEO of Twelve Bio, as recorded in our data. They have also founded this company.
Twelve Bio is a funded company, having raised a total of $2.57M across 2 funding rounds to date.
Twelve Bio has 10 employees.
Twelve Bio was established in 2019 as a spin-off from the Montoya group in Copenhagen, Denmark. Focus is placed on CRISPR-Cas12a, a protein that functions as a biological tool for detecting and modifying DNA sequences to generate new variants. Diagnostics and therapeutics are created using this technology. Support has been provided by organizations including the BioInnovation Institute, Novo Nordisk Fonden, and Novo Holdings. Operations center on biotechnology applications in healthcare.
Twelve Bio offers Engenious Platform.
Twelve Bio has 1 investor. Key investors include Ensoma.
The valuation of Twelve Bio is $6.93M as of Sep 2020.
Twelve Bio operates through Ensoma Aps.
Yes. Twelve Bio was acquired by Ensoma in January 2023.